We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





SARS-CoV-2 Test Uses Innovative Digital Microfluidics Technology for Accurate RT-PCR Testing with Rapid Turn-Around Time

By LabMedica International staff writers
Posted on 07 Apr 2021
A new RT-PCR test uses innovative digital microfluidics (DMF) technology for the qualitative detection of RNA from the SARS-CoV-2 virus in nasopharyngeal and nasal swab specimens within 17 minutes.

Baebies (Durham, NC, USA) has received acknowledgement from the US Food & Drug Administration (FDA) for the company’s Emergency Use Notification (EUN) for an RT-PCR test to detect SARS-CoV-2 on its FINDER 1.5 Instrument. More...
The company’s FINDER SARS‑CoV-2 Test is intended for the qualitative detection of RNA from the SARS-CoV-2 virus in nasopharyngeal and nasal swab specimens with RT-PCR performed within 17 minutes.

The FINDER 1.5 platform includes a toaster-sized instrument and disposable single-use cartridge and features a small footprint at just 8 inches wide with a commercial tablet interface, easy and intuitive workflow, and DMF technology, which minimizes sample and reagent volumes. The underlying DMF technology is a method to programmably manipulate tiny droplets of liquid by electrical control of surface tension on a disposable cartridge. Baebies’ DMF technology is protected by several hundred patents. Digital microfluidics supports multifunctional assay methods – including molecular, immunoassay, and chemistry – on the same cartridge. Baebies recently won the 2020 AACC Disruptive Technology Award for FINDER in a competition emerging as the next innovative testing solution that will transform patient care.

“Our FINDER SARS-CoV-2 test combines the accuracy of RT-PCR testing with a rapid turn-around time, which is made possible by our innovative digital microfluidics technology,” said Richard West, Co-Founder and Chief Executive Officer of Baebies. “We are launching the FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test to address the continued need for access to fast and accurate testing in health care facilities with high complexity laboratories.”

“In development of our FINDER SARS-CoV-2 Test, we focused on accelerating RT-PCR and sample processing for rapid results through several innovations – all made possible by digital microfluidics,” added Vamsee Pamula, co-founder and President. “This technology powers both our diagnostic platform, FINDER, and FDA-authorized newborn screening platform, SEEKER. Baebies’ core focus still remains neonatal and pediatric diagnostics, however, the current COVID-19 pandemic doesn’t distinguish between children and adults – everyone is at risk.”

Related Links:
Baebies


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.